Breast cancer patient recurrence risk 20 gene prediction model based on breast cancer single cell transcriptome sequencing analysis

Abstract

The invention relates to the field of gene detection technologies and biomedicine, in particular to a breast cancer patient recurrence risk 20 gene prediction model based on breast cancer single-celltranscriptome sequencing analysis and an establishment method and application thereof. The model is composed of 20 genes of CEBPD, SERPINA1, CD24, ERRFI1, BCL3, DSTN, BTG2, SERTAD1, SPINT1, BAMBI, LIMCH1, NFIA, SKP1, DHRS7, ODF3B, KRT7, ZFP36, CEBPB, BHLHE40 and UGDH. The breast cancer patient recurrence risk 20 gene prediction model provided by the invention provides more accurate judgment for long-term prognosis of a breast cancer patient, and provides a basis for selection of a postoperative adjuvant therapy scheme of the patient, so that individualized accurate treatment is realized, and meanwhile, a new research perspective is provided for research of breast cancer tumor stem cells.

Description

technical field [0001] The invention relates to the field of gene detection technology and biomedicine, in particular to a 20-gene prediction model for the recurrence risk of breast cancer patients based on single-cell transcriptome sequencing analysis of breast cancer and its establishment method and application. Background technique [0002] Breast cancer is the number one killer that endangers the health and life of human women. Although the postoperative survival rate is high, long-term recurrence and metastasis after many years of operation are common in clinical practice. At present, there is still a lack of sufficient reference information for the determination of further adjuvant treatment options for postoperative patients. Especially independent of the pathological and molecular types of the disease, postoperative adjuvant therapy that can be based on the fundamental universal applicability of breast cancer tumor cells still lacks sufficient prompting information a...

AI Technical Summary

Problems solved by technology

At present, there is still a lack of sufficient reference information for the determination of further adjuvant treatment options for postoperative patients

Especially independent of the pathological and molecular classification of the disease, postoperative adjuvant therapy based on the fundamental universal applicability of breast cancer tumor cells still lacks sufficient prompting information and indicators

The existing long-term postoperative recurrence prediction and the selection of adjuvant therapy are still based on the clinicopathological information of patients combined with the currently widely used 21-gene model, and its application still has certain limitations. For example, the 21-gene model is mainly used in luminal patients. Breast cancer, especially Luminal A breast cancer

Images